Janssen submits HCV combo to FDA

Share this article:

J&J's Janssen submitted a supplemental new drug application for HCV treatment Olysio (simeprevir) combined with sofosbuvir today for the treatment of genotype 1 patients with liver scarring (fibrosis).

Simeprevir was approved in November 2013 for patients with chronic HCV in combination with peginterferon and ribavirin. The drug was co-developed by Medivir AB.

MM&M reported in November that Janssen was “committed to patient education” for the drug, and would also offer diagnostic testing to providers in a bid to improve access.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.